Enbrel sBLA for psoriasis
Executive Summary
Amgen and Wyeth submit sBLA for Enbrel for the treatment of moderate to severe plaque psoriasis. Enbrel (etanercept) is the first anti-tumor necrosis factor product to be filed for the treatment of psoriasis; Centocor's Remicade (infliximab) is in Phase III trials for psoriasis and Abbott's Humira (adalimumab) is in Phase II...